secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2026-09-02T20:29:56+00:00
Accession:  0001628280-26-060124
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio receives Nasdaq delisting notices; amends financing, $2M NSG note sale
--------------------------------------------------------------------------------

- Nasdaq: bid price below $1.00 for 30 days; 180-day cure period to Feb 23, 2027.
- Stockholders' equity deficit of $3.4M vs $2.5M requirement; plan due Oct 11, 2026.
- Amendment authorizes $2.0M third-tranche note sale to NSG BioInnovation Fund.
- NSG purchase satisfies Celadon's remaining note purchase obligation under Merger Agreement.
- Contingent value right up to $60M tied to SENTI-202 milestones in proposed merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/0001628280-26-060124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/snti-20260827.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-060124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer